A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors

Trial Profile

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs BGB A317 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors BeiGene
  • Most Recent Events

    • 13 Nov 2017 Status changed from recruiting to active, no longer recruiting, according to a BeiGene media release.
    • 12 Sep 2017 Preliminary results (n=55) as of 6 MAR 2017 related to a subset of patients with advanced gastric cancer (GC) and esophageal carcinoma (EC) were presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Preliminary results from a subset of patients with advanced ovarian cancer (As of 6 Mar 2017; n=51) presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top